Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$96.94
+0.5%
$82.40
$60.40
$106.83
$18.42B0.92.29 million shs743,521 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$39.42
-0.1%
$32.73
$27.34
$60.87
$7.23B0.191.38 million shs519,399 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$24.99
+1.0%
$22.72
$7.89
$36.91
$18.59B-1.013.73 million shs706,642 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.63
-0.5%
$17.07
$12.47
$22.80
$19.07B0.610.27 million shs2.96 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
+0.34%-1.80%+36.49%+48.85%+37.28%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
+5.25%+9.89%+13.46%+26.15%-15.52%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+7.61%+9.37%+14.75%+22.78%+215.56%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.42%-2.05%-7.47%+30.17%+5.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Insmed, Inc. stock logo
INSM
Insmed
4.5455 of 5 stars
3.54.00.04.33.41.70.6
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.8951 of 5 stars
4.51.00.00.01.91.70.6
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.4762 of 5 stars
4.41.00.00.01.91.70.0
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
4.1997 of 5 stars
4.63.00.00.02.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$108.0711.48% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$72.6084.19% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.79
Moderate Buy$34.6738.72% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.25
Buy$24.7148.66% Upside

Current Analyst Ratings Breakdown

Latest LEGN, TEVA, INSM, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.00
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
7/8/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
7/2/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00 ➝ $54.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/26/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $23.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$363.71M50.56N/AN/A$1.60 per share60.59
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M11.55N/AN/A$5.70 per share6.91
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K26,513.32N/AN/A$0.53 per share47.15
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.15$3.37 per share4.94$4.74 per share3.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.320.85-7.74%45.44%6.95%7/30/2025 (Estimated)

Latest LEGN, TEVA, INSM, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64N/AN/AN/A$4.34 billionN/A
5/13/2025Q1 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/7/2025Q1 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
5/1/2025Q1 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
5.20
5.07
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
10.63
10.63
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.59
1.03
0.74

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.67 million112.14 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable

Recent News About These Companies

Teva (TEVA) Receives a Buy from Leader Capital Markets
Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Insmed stock logo

Insmed NASDAQ:INSM

$96.94 +0.47 (+0.48%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$39.42 -0.05 (-0.11%)
As of 12:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$24.99 +0.25 (+1.01%)
As of 12:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$16.62 -0.09 (-0.51%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.